Thursday, July 26, 2007

UPDATE 3-Celgene 2nd-qtr earnings jump on cancer drug sales

(Reuters) - BOSTON, July 26 - Celgene Corp. , the top maker of drugs to treat multiple myeloma, said on Thursday its second-quarter earnings rose on soaring sales of its newest product, Revlimid.



Net profit rose to $54.9 million, or 13 cents a share, from $9.6 million, or 3 cents a share, a year earlier.


Read more at Reuters.com Market News

No comments: